Jazz Pharmaceuticals (MEX:JAZZN) Research & Development: MXN14,599 Mil (TTM As of Mar. 2026)


MEX:JAZZN Jazz Pharmaceuticals PLC MEX:JAZZN
73 GF Score
Price MXN2,500.00
GF Value MXN1,641.59
! 6 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Research & Development?

Jazz Pharmaceuticals MEX:JAZZN 73 Research & Development is MXN14,599 Mil as of Mar. 2026. GuruFocus rates MEX:JAZZN with a GF Score™ of 73/100 and a GF Value™ of MXN1,641.59. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Jazz Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was MXN3,534 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was MXN14,599 Mil.

Jazz Pharmaceuticals  (MEX:JAZZN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Jazz Pharmaceuticals Research & Development Related Terms

Jazz Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals Research & Development Chart

Jazz Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,374.91 11,511.47 14,422.31 18,436.44 14,093.71

Jazz Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,696.80 3,577.02 3,635.88 3,851.58 3,534.41
MEX:JAZZN
73GF Score
Jazz Pharmaceuticals PLC MEX:JAZZN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jazz Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN14,599 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN14,599 Mil mean?
Jazz Pharmaceuticals (MEX:JAZZN) has a Research & Development of MXN14,599 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Research & Development too high?
Jazz Pharmaceuticals' current Research & Development is MXN14,599 Mil. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Research & Development compare to ASND and SMMT?
Jazz Pharmaceuticals' Research & Development of MXN14,599 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Research & Development is MXN14,599 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Jazz Pharmaceuticals (MEX:JAZZN) has a current Research & Development of MXN14,599 Mil. The stock's GF Value™ is MXN1,641.59, compared to a current price of MXN2,500.00 — trading 52.3% above its estimated fair value. The current Research & Development is MXN14,599 Mil. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Jazz Pharmaceuticals (MEX:JAZZN), the current Research & Development is MXN14,599 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (MEX:JAZZN) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of MXN2,500.00 is trading 52.3% above its estimated GF Value™ of MXN1,641.59.

Key valuation signals for MEX:JAZZN:

  • Research & Development: MXN14,599 Mil
  • GF Value™: MXN1,641.59 vs. price of MXN2,500.00 (52.3% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the MEX:JAZZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score

Get the complete analysis for MEX:JAZZN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,500.00
Price
MXN1,641.59
GF Value